Highest-materiality recent filing
Glucotrack receives second Nasdaq delisting notice; plans to appeal by May 18
First notice on May 11: non-compliance with minimum bid price of $1.00.
Glucotrack Q1 net loss $4.3M, IDE submitted to FDA for implantable CGM
Net loss $4.3M vs $6.8M YoY; cash $3.9M as of March 31, 2026.
Study in Journal of Diabetes Research shows weighted average MARD of 6.8% across 79 IV glucose tolerance tests in ovine model.
Glucotrack reports FY2025 net loss $19.4M; cash $7.4M; plans IDE filing Q2 2026
Net loss for FY2025 was $19.4M, down from $22.6M in 2024; no product revenue.
Glucotrack to file IDE with FDA for implantable CBGM in Q2 2026, citing positive trial results
Brazil first-in-human study (Dec 2024-Jan 2025) showed MARD 7.7%, 99% data capture, and zero serious adverse events.
Glucotrack receives USPTO approval for three CBGM patents
Three US patents issued by USPTO: US 12,453,494 (Oct 28, 2025), US 12,458,257 and US 12,458,258 (Nov 4, 2025).
Q3 2025 net loss $4.2M ($4.64 per share) vs $5.1M in Q3 2024; nine-month net loss $15.8M.
Special Meeting reconvenes November 7, 2025 at 12 p.m. ET to vote on Equity Purchase Agreement with Sixth Borough Capital Fund LP.
Glucotrack issues $3.6M convertible note at $3M price; ELOC proceeds to repay
Issued $3.6M convertible promissory note for $3M purchase price ($600K OID), no interest, due in 12 months or upon Qualified Financing.
Glucotrack signs up to $20M equity purchase agreement with Sixth Borough Capital Fund
Investor committed to buy up to $20M of common stock over 24 months at company's discretion.
Net loss of $11.6M for H1 2025 vs $7.4M prior year; operating expenses rose $0.9M.
Glucotrack appoints David S. Hirsh, MD as Medical Director, Cardiology
Dr. Hirsh, a cardiac electrophysiologist, joins Glucotrack's clinical advisory team for its CBGM program.
Glucotrack to exhibit CBGM at ADCES; touts progress toward US pilot study
Presenting at ADCES Annual Meeting Aug 8-11, 2025 in Phoenix, AZ; CBGM at Booth #1724.
Glucotrack repurchases ~49,700 Series A warrants, cuts potential dilution
Repurchased over 90% of Series A Warrants on June 30, 2025 for cash on hand in a negotiated transaction.
Glucotrack reports positive final first-in-human CBGM study results with MARD 7.7%
Study met all endpoints; MARD 7.7% across 122 matched pairs, 99% data capture, no serious adverse events.
Glucotrack executes 1-for-60 reverse stock split effective June 13, 2025
Reverse split approved by stockholders on May 22; reduces outstanding shares from 34,047,337 to ~567,456.
1-for-60 reverse stock split approved by shareholders on May 22, 2025, effective at market open on June 16, 2025.
All five director nominees elected with ~59% of votes cast in favor; broker non-votes amounted to ~5.45M on each nominee.
Glucotrack Q1 net loss widens to $6.8M; cash $9.1M; on track for CBGM study Q3 2025
Net loss $6.8M vs $2.9M YoY; includes $3.4M non-cash derivative liability change.
Glucotrack receives ethics approval for 1-year CBGM clinical study in diabetes patients
Ethical approval from St. Vincent's Hospital Melbourne HREC for long-term CBGM study in type 1/2 diabetes.
Glucotrack joins EU-funded FORGETDIABETES bionic pancreas initiative
Glucotrack's CBGM will provide real-time glucose data for automated insulin delivery system.
Glucotrack receives Nasdaq delisting notice for bid price non-compliance; plans to appeal
Nasdaq notified Glucotrack on April 2, 2025 of delisting due to bid price below $1.00 for 30 consecutive business days.
Glucotrack FY2024 net loss $22.6M; completes first human CBGM study, expects IDE in Q4 2025
Net loss of $22.6M vs $7.1M in 2023; R&D expense $9.5M (+$4.8M YoY) on increased product development activities.
Glucotrack to present first-in-human CBGM trial data at ATTD 2025 conference in Amsterdam
Safety and performance data from first-in-human trial of implantable CBGM system to be presented at ATTD conference, March 19-22, 2025.
Glucotrack issues 2.75M shares after cashless warrant exchange
Exchange of 2,835,905 Series B warrants on March 11, 2025 resulted in 2,749,817 new common shares.
Effective Feb 3, 2025, every 20 pre-split shares combined into 1 share; outstanding shares reduced from ~155.5M to ~7.8M.
Glucotrack announces 1-for-20 reverse stock split to regain Nasdaq compliance effective Feb 4, 2025
1-for-20 reverse split effective at market open on Feb 4, 2025; shares reduce from ~155.5M to ~7.77M.
Glucotrack CFO James Cardwell resigns; Peter Wulff appointed as CFO
James Cardwell resigned as CFO effective Jan 27, 2025; will remain as consultant for transition.
Glucotrack corrects warrant exchange shares; 134.8M shares issued for 6.95M warrants
Holders exchanged 6,950,240 Series B Warrants for 134,785,015 common shares from Jan 6-13, 2025.
Glucotrack issues 134.8M shares upon cashless exchange of 6.95M Series B Warrants
Holders exchanged 6,950,240 Series B Warrants for 134,785,015 shares of common stock.
On January 27, 2025, James Cardwell informed the Board of Directors (the “Board”) of Glucotrack, Inc. (the “Company”) that he was resigning as Chief Financial Officer of the Company, effective immediately.
In connection with Mr. Cardwell’s resignation, on January 28, 2025, the Board appointed Peter C. Wulff as Chief Financial Officer of the Company.
On August 27, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Paul V. Goode, and Mr. John Ballantyne to the Board of Directors (the “Board”) as board members.
On August 27, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Paul V. Goode, and Mr. John Ballantyne to the Board of Directors (the “Board”) as board members.
On July 29, 2024, Shimon Rapp and Andrew Sycoff resigned from the board of directors.
On July 29, 2024, Shimon Rapp and Andrew Sycoff resigned from the board of directors.
On June 14, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Andrew K. Balo to the Board of Directors as an independent board member.
Max materiality 0.85 · Median 0.60 · Most common event other_material